TVGNW
Tevogen Bio Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.05
+1.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 205.0K | — | 403.6K | 378.4K | — |
| Gross Profit | (205.0K) | — | (403.6K) | (378.4K) | — |
| Operating Expenses | |||||
| R&D Expense | 11.6M | 11.1M | 31.0M | 4.4M | — |
| SG&A Expense | 9.8M | 15.0M | 22.1M | 4.1M | 953.1K |
| General & Admin Expense | 9.8M | 15.0M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (205.0K) | — | — | — | — |
| Total Operating Expenses | 21.2M | 26.1M | 53.2M | 8.5M | 953.1K |
| Cost and Expenses | 21.4M | 26.1M | 53.6M | 8.8M | 953.1K |
| Operating Income (EBIT) | (21.4M) | (26.1M) | (53.6M) | (8.8M) | (953.1K) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 4.9M |
| Interest Expense | 160.2K | 195.6K | 184.0K | 256.0K | — |
| Net Interest Income | (160.2K) | (195.6K) | (184.0K) | (256.0K) | 4.9M |
| Other Non-Op Income/Expense | (209.7K) | (134.9K) | 39.8M | (51.6M) | 5.4M |
| Non-Operating Income (excl Interest) | 48.2K | (60.7K) | (40.0M) | 50.4M | (5.4M) |
| EBT (Pre-Tax Income) | (21.6M) | (26.3M) | (13.7M) | (60.5M) | 4.4M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (21.6M) | (26.3M) | (10.1M) | (60.5M) | 4.4M |
| Earnings from Cont. Ops | (21.6M) | (26.3M) | (13.7M) | (60.5M) | 4.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (21.3M) | (26.3M) | (10.3M) | (60.5M) | 4.4M |
| Per Share | |||||
| Basic EPS | ($5.83) | ($8.08) | ($4.68) | ($0.02) | $1.84 |
| Diluted EPS | ($5.83) | ($8.08) | ($4.68) | ($0.02) | $1.84 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.8M | 3.3M | 2.9M | 3.3M | 2.4M |
| Diluted Shares Outstanding | 3.8M | 3.3M | 2.9M | 3.3M | 2.4M |
| Profitability Metrics | |||||
| EBITDA | (21.0M) | (25.6M) | (13.1M) | (58.9M) | 4.6M |
| D&A | 496.4K | 509.2K | 403.6K | 378.4K | 230.8K |
| EBIT | (21.5M) | (26.1M) | (13.5M) | (59.3M) | 4.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026